Idarubicin more cost-effective than daunorubicin?
Hillman
A L
AL
School of Medicine, University of Pennsylvania, Philadelphia.
D003362:Cost-Benefit Analysis; D003630:Daunorubicin / Q000191:economics* / Q000627:therapeutic use; D017722:Hospital Charges; D017721:Hospital Costs; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome